Until Which Age Should Women Be Vaccinated Against HPV Infection? Recommendation Based on Cost-effectiveness Analyses

Cost-Effectiveness of Human Papillomavirus Vaccination and Cervical Cancer Screening in Women Older Than 30 Years in the United States

(2013) Jane J. Kim   ANNALS OF INTERNAL MEDICINE

Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20–29 in the UK

(2010) J Cuzick et al.   BRITISH JOURNAL OF CANCER

Cost–effectiveness of catch-up programs in human papillomavirus vaccination

(2010) Maria A de Peuter et al.   Expert Review of Vaccines

Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection

(2010) Sven-Eric Olsson et al.   Human vaccines & immunotherapeutics

Comparison of the immunogenicity and safety ofCervarix™ andGardasil®human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years

(2010) Mark H. Einstein et al.   Human vaccines & immunotherapeutics

Efficacy of Human Papillomavirus Vaccines

(2010) Lidia Rosi Medeiros et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women

(2010) Nubia Muñoz et al.   JNCI-Journal of the National Cancer Institute

Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women

(2010) N. De Carvalho et al.   VACCINE

A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions

(2009) S. K. Kjaer et al.   Cancer Prevention Research

The current state of introduction of HPV vaccination into national immunisation schedules in Europe: Results of the VENICE 2008 survey

(2009) D. Lévy-Bruhl et al.   EUROPEAN JOURNAL OF CANCER

Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: Modeling of sustained antibody responses☆

(2009) Marie-Pierre David et al.   GYNECOLOGIC ONCOLOGY

The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV‐Naive Women Aged 16–26 Years

(2009) Darron R. Brown et al.   JOURNAL OF INFECTIOUS DISEASES

Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6·4 years

(2009)   LANCET

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial

(2009) Nubia Muñoz et al.   LANCET

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

(2009) J Paavonen et al.   LANCET

Economic Evaluation of Human Papillomavirus Vaccination in Developed Countries

(2009) Marc Brisson et al.   Public Health Genomics

Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: Adaptation of an existing cohort model to the situation in the Netherlands

(2009) R.M. Rogoza et al.   VACCINE

Efficacy, duration of immunity and cross protection after HPV vaccination: A review of the evidence

(2009) Paolo Bonanni et al.   VACCINE

Determinants for HPV vaccine uptake in the Netherlands: A multilevel study

(2009) Marc Rondy et al.   VACCINE

Age-Specific Prevalence of Infection with Human Papillomavirus in Females: A Global Review

(2008) Jennifer S. Smith et al.   JOURNAL OF ADOLESCENT HEALTH

Health and Economic Implications of HPV Vaccination in the United States

(2008) Jane J. Kim et al.   NEW ENGLAND JOURNAL OF MEDICINE

Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: A multi-regional health economic analysis

(2008) Raina M. Rogoza et al.   VACCINE

Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15–55 years

(2008) Tino F. Schwarz et al.   VACCINE

Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester: prospective cohort study

(2008) Loretta Brabin et al.   BMJ-British Medical Journal